373 related articles for article (PubMed ID: 16000561)
21. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
[TBL] [Abstract][Full Text] [Related]
22. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
23. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
Jang JY; Park YC; Song YS; Lee SE; Hwang DW; Lim CS; Lee HE; Kim WH; Kim SW
J Hepatobiliary Pancreat Surg; 2009; 16(5):668-74. PubMed ID: 19412570
[TBL] [Abstract][Full Text] [Related]
24. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
Hamada S; Satoh K; Fujibuchi W; Hirota M; Kanno A; Unno J; Masamune A; Kikuta K; Kume K; Shimosegawa T
Mol Cancer Res; 2012 Jan; 10(1):3-10. PubMed ID: 22064652
[TBL] [Abstract][Full Text] [Related]
25. Effect of Reprimo Down-regulation on Malignant Transformation of Intraductal Papillary Mucinous Neoplasm.
Nakazato T; Suzuki Y; Tanaka R; Abe N; Masaki T; Mori T; Ohkura Y; Sugiyama M
Pancreas; 2018 Mar; 47(3):291-295. PubMed ID: 29401170
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
[TBL] [Abstract][Full Text] [Related]
27. CD44v6 expression in intraductal papillary mucinous neoplasms of the pancreas.
Miyasaka Y; Nagai E; Ohuchida K; Nakata K; Hayashi A; Mizumoto K; Tsuneyoshi M; Tanaka M
Pancreas; 2010 Jan; 39(1):31-5. PubMed ID: 19952968
[TBL] [Abstract][Full Text] [Related]
28. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
[TBL] [Abstract][Full Text] [Related]
29. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A
Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194
[TBL] [Abstract][Full Text] [Related]
30. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas.
Uehara H; Nakaizumi A; Ishikawa O; Iishi H; Tatsumi K; Takakura R; Ishida T; Takano Y; Tanaka S; Takenaka A
Gut; 2008 Nov; 57(11):1561-5. PubMed ID: 18477671
[TBL] [Abstract][Full Text] [Related]
31. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer.
Yamamura A; Miura K; Karasawa H; Morishita K; Abe K; Mizuguchi Y; Saiki Y; Fukushige S; Kaneko N; Sase T; Nagase H; Sunamura M; Motoi F; Egawa S; Shibata C; Unno M; Sasaki I; Horii A
Biochem Biophys Res Commun; 2013 Nov; 441(1):102-7. PubMed ID: 24134849
[TBL] [Abstract][Full Text] [Related]
32. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.
Yoshida K; Nagasaka T; Umeda Y; Tanaka T; Kimura K; Taniguchi F; Fuji T; Shigeyasu K; Mori Y; Yanai H; Yagi T; Goel A; Fujiwara T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1557-69. PubMed ID: 27095449
[TBL] [Abstract][Full Text] [Related]
33. Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: its association with tumor progression and proliferation.
Hayashi A; Aishima S; Miyasaka Y; Nakata K; Morimatsu K; Oda Y; Nagai E; Oda Y; Tanaka M; Tsuneyoshi M
Hum Pathol; 2010 Nov; 41(11):1507-15. PubMed ID: 20656320
[TBL] [Abstract][Full Text] [Related]
34. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
Xu S; Furukawa T; Kanai N; Sunamura M; Horii A
J Hum Genet; 2005; 50(4):159-167. PubMed ID: 15824892
[TBL] [Abstract][Full Text] [Related]
35. REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms.
Nakata K; Nagai E; Ohuchida K; Aishima S; Hayashi A; Miyasaka Y; Yu J; Mizumoto K; Tanaka M; Tsuneyoshi M
Mod Pathol; 2009 Mar; 22(3):460-8. PubMed ID: 19136934
[TBL] [Abstract][Full Text] [Related]
36. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.
He H; Di Y; Liang M; Yang F; Yao L; Hao S; Li J; Jiang Y; Jin C; Fu D
Oncol Rep; 2013 Aug; 30(2):651-8. PubMed ID: 23733161
[TBL] [Abstract][Full Text] [Related]
37. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
38. Multiple mechanisms downregulate CDKN1C in human bladder cancer.
Hoffmann MJ; Florl AR; Seifert HH; Schulz WA
Int J Cancer; 2005 Apr; 114(3):406-13. PubMed ID: 15551363
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas.
Lubezky N; Loewenstein S; Ben-Haim M; Brazowski E; Marmor S; Pasmanik-Chor M; Oron-Karni V; Rechavi G; Klausner JM; Lahat G
Surgery; 2013 May; 153(5):663-72. PubMed ID: 23305591
[TBL] [Abstract][Full Text] [Related]
40. [Pathologic characteristics and evaluation of the pancreatic cancer].
Fukushima N; Mukai K
Gan To Kagaku Ryoho; 2005 May; 32(5):599-604. PubMed ID: 15918557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
